astonea
Astonea Labs Limited

Date: 24th July, 2026
To,
BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001

Scrip Code: 544409
ISIN: INE0TG901011

SUBJECT: OUTCOME OF THE MEETING OF THE BOARD OF DIRECTORS OF ASTONEA LABS LIMITED HELD ON 24th JULY, 2026

Pursuant to the provisions of Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors of Astonea Labs Limited ("the Company"), at its meeting held on **Friday, 24th July, 2026**, at the Corporate Office of the Company situated at 63, Industrial Area, Phase-II, Panchkula, Haryana - 134113, inter alia, considered, deliberated upon and approved the following matters:

1. **APPROVAL OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR AND FINANCIAL YEAR ENDED 31ST MARCH, 2026**

The Board of Directors, at its meeting held on 24 July, 2026, considered and approved the Audited Consolidated Financial Results of the Company for the half year and financial year ended 31st March, 2026, together with the Audited Consolidated Financial Statements comprising the Consolidated Balance Sheet, Consolidated Statement of Profit and Loss, Consolidated Statement of Cash Flows and the Notes forming part thereof, and took on record the Statutory Auditors' Report issued thereon containing an unmodified opinion.

The Board further approved the declaration pursuant to Regulation 33(3)(d) of the SEBI Listing Regulations, confirming that the Statutory Auditors have expressed an unmodified opinion on the aforesaid Audited Consolidated Financial Results and authorised the submission thereof to the Stock Exchange.

The Board further noted that the Audited Consolidated Financial Results for the financial year ended 31st March, 2026 could not be considered and approved at its earlier meeting held on 30th May, 2026 since the audit report of the Associate Company was still awaited at the time of the Board Meeting. Accordingly, only the Audited Standalone Financial Results of the Company for the financial year ended 31st March, 2026 were considered and approved at the said meeting. Upon receipt of the audited financial statements of the Associate Company i.e. Damaira Pharmaceuticals Private Limited, the Board has now duly considered and approved the Audited Consolidated Financial Results at the present meeting.

The Board further noted that, pursuant to the resolution passed at its meeting held on 25th May, 2026, Mr. Pardeep Dalal (DIN: 02424111) was duly authorised as the signing authority on behalf of the Company for signing and certifying the Financial Results in accordance with the requirements of Regulation 33 of the SEBI Listing Regulations. The Company had already intimated the aforesaid authorisation to the Stock Exchange vide its response dated 20th June, 2026, submitted against the query/email received from the Stock Exchange dated 19th June, 2026. Accordingly, the Audited Consolidated Financial Results approved at the present meeting have been signed and certified by the said authorised signatory in accordance with the aforesaid Board authorisation.

The Board further noted that the Trading Window for dealing in the securities of the Company, which has remained closed with effect from 01st April, 2026 pursuant to the provisions of the Company's Code of Conduct for Prevention of Insider Trading and the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, shall stand reopened upon expiry of 48 (Forty-Eight) hours from the declaration and approval of the Audited Consolidated Financial Results of the Company for the half year and financial year ended 31st March, 2026.

For more details, kindly refer Annexure-I containing Audited Consolidated Financial Results.

2. APPROVAL OF BOARD'S REPORT FOR THE FINANCIAL YEAR 2025-26

The Board of Directors considered, reviewed and approved the draft Board's Report of the Company for the financial year ended 31st March, 2026, along with the annexures forming part thereof, as placed before the Board. After due deliberation and review, the Board approved and adopted the said Board's Report in accordance with the provisions of Section 134 and other applicable provisions of the Companies Act, 2013 read with the rules made thereunder. The Board's Report, as approved, contains the requisite disclosures, statements and information as required under the applicable provisions of the Companies Act, 2013, rules framed thereunder and other applicable statutory requirements.

3. APPROVAL OF ANNUAL REPORT FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2026

The Board of Directors considered, reviewed and approved the Annual Report of the Company for the financial year ended 31st March, 2026 ("Financial Year 2025-26) as placed before the Board. The said Annual Report comprises, inter alia, the Audited Financial Statements of the Company, Board's Report, Statutory Auditors' Report and other statements, disclosures, certificates and information forming an integral part thereof, as required under the applicable provisions of the Companies Act, 2013, the rules made thereunder and other applicable statutory and regulatory requirements.

After due deliberation and review, the Board approved and adopted the Annual Report of the Company for the financial year ended 31st March, 2026, and authorised the Directors of the Company to sign and authenticate the same on behalf of the Board of Directors in accordance with the applicable provisions of the Companies Act, 2013.

4. RETIREMENT BY ROTATION AND RECOMMENDATION FOR RE-APPOINTMENT OF MS. POOJA SINGH (DIN: 10547745) AS DIRECTOR OF THE COMPANY

The Board of Directors, pursuant to the provisions of Section 152 and other applicable provisions of the Companies Act, 2013 read with the rules made thereunder, took note of the retirement by rotation of Ms. Pooja Singh (DIN: 10547745), Director of the Company, at the ensuing Annual General Meeting of the Company.

The Board further noted that Ms. Pooja Singh, being eligible for re-appointment and having offered herself for re-appointment as a Director of the Company, has submitted her consent and requisite declarations in accordance with the applicable provisions of the Companies Act, 2013 and rules made thereunder.

After due consideration and deliberation, the Board considered and recommended the proposal for re-appointment of Ms. Pooja Singh as a Director of the Company for consideration and approval of the members at the ensuing Annual General Meeting of the Company in accordance with the applicable provisions of the Companies Act, 2013.

For more details, kindly refer Annexure-II.

5. <u>ALTERATION OF OBJECT CLAUSE OF THE MEMORANDUM OF ASSOCIATION (MOA) OF THE COMPANY</u>

The Board of Directors considered and approved the proposal for alteration of the Object Clause (Clause III(A)) of the Memorandum of Association ("MOA") of the Company pursuant to the provisions of Section 13 and other applicable provisions, if any, of the Companies Act, 2013 read with the rules made thereunder.

The Board approved the substitution of the existing Object Clause III(A) of the MOA with the revised clauses relating to undertaking business activities in the areas of manufacturing, formulation, processing, development, refining, import, export, wholesale and retail trading of pharmaceuticals, medicines, healthcare products, nutraceuticals, ayurvedic, herbal and dietary supplement products and other allied products.

The Board further approved inclusion of activities relating to marketing, promotion, distribution and sale of the Company's products through various lawful distribution channels, including retail networks, wholesale trade, institutional sales, franchise arrangements, e-commerce platforms, digital marketplaces and other legally recognized modes of distribution.

The Board further decided that the proposed alteration of the Object Clause of the MOA shall be placed before the members of the Company for their approval by way of a Special Resolution at the ensuing General Meeting.

For more details, kindly refer Annexure-III.

6. <u>APPROVAL FOR INCORPORATION AND INVESTMENT IN WHOLLY OWNED SUBSIDIARY AND/OR SUBSIDIARY COMPANY(IES) IN INDIA</u>

The Board of Directors considered and approved the proposal for incorporation, promotion, subscription to the Memorandum and Articles of Association and investment in the share capital of one or more subsidiary company(ies) in India, with a view to expanding the business operations of the Company and strengthening its presence in various business segments.

The Board noted that the proposed subsidiary company(ies) shall undertake such business activities as may be approved by the Board from time to time, in accordance with the strategic objectives and growth plans of the Company and subject to compliance with applicable laws.

The Board further noted that the proposed incorporation and investment in subsidiary company(ies) would facilitate focused business operations, enhance operational efficiency, explore new business opportunities and contribute towards the long-term growth and expansion objectives of the Company.

The Board was further apprised that the proposed investment in subsidiary company(ies) shall be undertaken in compliance with the applicable provisions of the Companies Act, 2013, including Sections 179 and 186 thereof, and other applicable statutory requirements.

After due deliberation and consideration, the Board approved the proposal for incorporation and investment in one or more subsidiary company(ies) in India and authorized the Directors, Key Managerial Personnel and authorized officers of the Company to take all necessary steps in this regard.

7. APPROVAL OF NOTICE CONVENING THE 9TH ANNUAL GENERAL MEETING OF THE COMPANY

The Board of Directors considered and approved the draft Notice convening the 9th Annual General Meeting ("AGM") of the Company for the financial year 2025-26, along with the explanatory statement pursuant to Section 102 of the Companies Act, 2013 and other documents forming part thereof, as placed before the Board.

The Board was apprised that the 9th Annual General Meeting of the Company is proposed to be convened on Friday, 21st August, 2026 at 11:30 A.M. at Mercure Hotel, Plot No. 51, Near Tribune Chowk, Industrial Area Phase II, Chandigarh-160002, to transact the businesses as set out in the approved Notice of the AGM.

After due consideration and deliberation, the Board approved the Notice of the 9th Annual General Meeting along with the accompanying documents in accordance with the applicable provisions of the Companies Act, 2013, rules made thereunder and Secretarial Standard-2 ("SS-2") on General Meetings issued by the Institute of Company Secretaries of India.

For more details, kindly refer Annexure-IV

8. APPROVAL FOR APPOINTMENT OF NATIONAL SECURITIES DEPOSITORY LIMITED (NSDL) AS THE E-VOTING AGENCY FOR THE ENSUING ANNUAL GENERAL MEETING OF THE COMPANY

The Board of Directors considered and approved the proposal for appointment of National Securities Depository Limited (NSDL) as the e-voting agency for providing remote e-voting and e-voting facility for the 9th Annual General Meeting ("AGM") of the Company.

The Board was apprised that the appointment of NSDL as the e-voting agency would facilitate the Company in providing electronic voting facilities to its members in accordance with the applicable provisions of the Companies Act, 2013, rules made thereunder and Secretarial Standard-2 ("SS-2") on General Meetings issued by the Institute of Company Secretaries of India.

After due deliberation and consideration, the Board approved the appointment of NSDL as the e-voting service provider for the ensuing Annual General Meeting of the Company.

9. APPROVAL FOR APPOINTMENT OF MR. SAHIL MALHOTRA AS THE SCRUTINIZER FOR THE ENSUING ANNUAL GENERAL MEETING OF THE COMPANY

The Board of Directors considered and approved the proposal for appointment of Mr. Sahil Malhotra (Membership No. A38204 / COP No. 14791) as the Scrutinizer for the 9th Annual General Meeting ("AGM") of the Company.

The Board was apprised that the appointment of the Scrutinizer is required for scrutinizing the voting process, including remote e-voting and e-voting facility provided during the AGM, in a fair and transparent manner in accordance with the provisions of Section 108 and other applicable provisions, if any, of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Secretarial Standard-2 ("SS-2") on General Meetings issued by the Institute of Company Secretaries of India.

After due deliberation and consideration, the Board approved the appointment of Mr. Sahil Malhotra as the Scrutinizer for the ensuing Annual General Meeting of the Company and authorized him to scrutinize the voting process and submit his report thereon in accordance with the applicable provisions of law.

10. <u>APPROVAL FOR DEFERRAL OF THE PROPOSAL FOR TERMINATION OF AGREEMENTS EXECUTED WITH ASTONEA ONE PRIVATE LIMITED</u>

The Board of Directors considered and took note of the proposal for termination of the Material Supply & Manufacturing Agreement dated 01.05.2024 and the Distribution, Marketing & Brand License Agreement dated 01.08.2025 executed between the Company and Astonea One Private Limited**,** along with the proposed revocation of all rights granted thereunder with effect from 01.07.2026, as previously considered and approved by the Board.

The Board discussed the matter and after due consideration, decided to defer the implementation of the aforesaid termination proposal, including issuance of termination notices, revocation of rights, withdrawal of licenses, discontinuation of arrangements and other consequential actions contemplated thereunder, until further notice.

The Board further noted that, until any further decision is taken by the Board, the existing contractual arrangements, rights and obligations between the Company and Astonea One Private Limited shall continue to remain in force and shall be governed by the respective terms and conditions of the agreements executed between the parties.

The Board authorized any Director and/or the Company Secretary of the Company to communicate the decision of the Board to the concerned parties, maintain necessary records and undertake all such acts, deeds, matters and things as may be necessary, expedient or incidental for giving effect to the aforesaid decision.

11. <u>APPROVAL FOR AMENDMENT TO ITEM NO. 15 OF THE BOARD RESOLUTION DATED 30TH MAY, 2026 RELATING TO THE APPOINTMENT OF THE TAX AUDITOR</u>

The Board of Directors considered and approved the proposal for amendment to Item No. 15 of the Board Resolution dated 30th May, 2026 relating to the appointment of the Tax Auditor of the Company.

The Board was apprised that the amendment was required to update the statutory references in the aforesaid resolution in accordance with the applicable provisions of the Income-tax Act, 2025, including Section 63 thereof, and other applicable provisions of law, rules and regulations made thereunder.

The Board further noted that the reference to the Income-tax Act, 1961 and Section 44AB thereof contained in the Board Resolution dated 30th May, 2026 shall stand amended and substituted with the reference to the Income-tax Act, 2025, including Section 63 thereof, and other applicable provisions as may be applicable from time to time.

After due deliberation and consideration, the Board approved the re-appointment of M/s. Avnish Sharma & Associates, Chartered Accountants (Firm Registration No. 009398N) as the Tax Auditor of the Company for the Tax Year 2026-27 (corresponding to the Financial Year ending 31st March, 2027), to conduct the tax audit and undertake such other certifications, reports and compliances as may be required under the applicable provisions of law.

The Board further approved the remuneration of the Tax Auditor for the Tax Year 2026-27, as mutually agreed between the Company and the Tax Auditor.

The Board noted that except for the aforesaid amendment relating to statutory references and terminology, all other terms, conditions and provisions of the Board Resolution dated 30th May, 2026 shall remain unchanged and continue to be in full force and effect.

For more details, kindly refer Annexure-V

The meeting of the Board of Directors commenced at 02:00 P.M. and concluded at 05:10 P.M.

We respectfully request that the Exchange be pleased to take cognizance of the aforesaid submission for its information and records.

Thanking you.

Yours faithfully,
For **ASTONEA LABS LIMITED**

Ankit Kapoor Digitally signed by Ankit Kapoor Date: 2026.07.24 17:30:14 +05'30'

ANKIT KAPOOR
COMPANY SECRETARY & COMPLIANCE OFFICER
M.NO. A75702

AVNISH SHARMA & ASSOCIATES
CHARTERED ACCOUNTANTS
#49, SUSHILA VILLA, SECTOR 7, PANCHKULA, HARYANA-134109
SCO 39, FF, SECTOR 20-C, DAKSHIN MARG, CHANDIGARH, 160020
Phone no. : (O) 0172-3500880, 3500881 (M) 9872980396
E-mail: avnishca@hotmail.com
Peer Review Certificate No. 016702
MSME Reg. No. UDYAM-CH-01-0010088

Independent Auditor's Report on Half Year and Financial year to date Audited Consolidated Financial Results of the company pursuant to Regulations 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (as amended)

To
The Board of Directors
ASTONEA LABS LIMITED
(Formerly Known as Astonea Labs Private Limited)

Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying statement of Consolidated Financial Results of ASTONEA LABS LIMITED ("Company") and its associate "Damaira Pharmaceuticals Private Limited"(Company and the associate together referred to as 'The Company'), for the Half Year and Financial year ended 31st March, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, and as per audited financial statements of the associate, as referred to in paragraph "other matters" below, the statement:

(a) includes the results of the Company - Astonea Labs Limited and Associate company-Damaira Pharmaceuticals Pvt. Ltd.;

(b) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended ("the Listing Regulation"); and

(c) gives a true and fair view in conformity with the applicable Accounting Standards, other accounting principles generally accepted in India, of the consolidated total profit (comprising of net profit) and other financial information of the company for the Half Year and year ended 31st March 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the Half Year and year ended 31st March 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and in terms of our reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Consolidated Financial Results

The Statement of Consolidated Financial Results for the Half Year and financial year ended 31st March, 2026 have been prepared on the basis of the consolidated financial statements for the financial year ended 31st March, 2026.

AVNISH SHARMA & A...
CHARTERED ACC...

The Company's Board of Directors are responsible for the preparation and presentation of these Consolidated Financial Results that give a true and fair view of the net profit and other financial information of the company in recognition and measurement principles laid down in Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated Financial Results by the Directors of the Company, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the company are responsible for assessing the ability of the company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the company are responsible for overseeing the financial reporting process of the companies included in the company.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the Half Year and Financial year ended 31st March 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Results.

As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of Consolidated Financial Statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Consolidated Financial Results, including the disclosures, and whether the Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the company to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors.

MANISH SHARMA & ASSOCIATES CHARTERED ACCOUNTANTS

We communicate with those charged with governance of the Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter
The consolidated annual financial results include the share of profit of Rs.2,970 (25.74% of Rs.42,12,220 for 1 day) of an associate company i.e. Damaira Pharmaceutical Private Limited, which have been audited by its independent auditor's. The independent auditor's report on financial statements of this entity have been furnished to us by the management and our statement in so far it relates to the amounts and disclosures included in respect to the associate is based solely on the reports of other independent auditor of associate company.

The Consolidated Financial Results includes the results for the half-year ended 31st March, 2026,being the balancing figures between the audited figures in respect of full financial year ended 31st March 2026 and the unaudited year to date figures up to 30th sept 2025 of the current financial year under reporting, which were subject to a limited review by us as required under the listing obligations.

The previous year figure for the year ended 31.03.2025 were only for Astonea Labs Limited as the investment in associate was made on 31.03.2026. For the year ended March, 2026 the Company has prepared and presented consolidated financial results, incorporating the financial information of its associate entity, as applicable.

During the preparation of the consolidated financial results, the Company has included its share of the Associate Company's profit for one day , representing the period from the date on which significant influence was obtained up to the reporting date i.e 31.03.2026.

As per our report of even date attached
For Avnish Sharma & Associates
Chartered Accountants
FRN - 009398N
Peer Review Certificate No. 016702

Avnish Sharma & Associates
Chartered Accountants

Rajan Talwar (M.No. 091352)
Partner
UDIN: 26091352NYXMCS2741
Place : Panchkula
Dated : 24.07.2026

ASTONEA LABS LIMITED

(Formerly known as Astonea Labs Private Limited)

Registered Office: SCO 321-322, Basement, Sector-35B, Chandigarh, 160022, India

CIN : L24304CH2017PLC041482

CONSOLIDATED STATEMENT OF AUDITED ASSET AND LIABILITIES AS AT 31ST MARCH 2026

Amount in ₹ (lakhs)

PARTICULARS	For the year ended March 31, 2026	For the year ended March 31, 2025
I. EQUITY AND LIABILITIES		
1 Shareholders' Funds		
(a) Share Capital	1,051.10	772.10
(b) Reserves And Surplus	4,662.07	1,069.19
(c) Money received against share warrants	-	-
2 Share application money pending allotment	-	-
3 Non-Current Liabilities		
(a) Long-Term Borrowings	2,073.10	1,960.54
(b) Deferred Tax Liabilities (Net)	-	3.12
(c) Other Long term liabilities	7.73	-
(d) Long term provisions(Gratuity)	43.21	32.95
4 Current Liabilities		
(a) Short Term borrowings	2,227.31	3,373.16
(b) Trade Payables	-	
1 Total outstanding dues of micro enterprises and small enterprises	1,085.83	576.18
2 Total outstanding dues of creditors other than micro enterprises and small	2,961.30	2,047.83
(c) Other Current Liabilites	488.01	346.38
(d) Short Term Provisions	26.34	156.62
TOTAL	**14,626.00**	**10,338.07**
II. ASSETS		
1 Non-Current Assets		
(a) Property, Plant & Equipments and Intangible Assets		
(a) Property Plant & Equipment	3,103.79	2,539.76
(b) Intangible Assets	31.53	23.34
(c) Capital Work in Progess	767.67	440.57
(b) Non -Current Investment	625.64	-
(c) Deferred Tax Assets (Net)	55.48	-
(d) Long term loans & advances	-	15.02
(e) Other Non-Current Assets	233.02	234.39
2 Current assets		
(a) Current Investment	-	-
(b) Inventories	3,360.89	2,934.99
(c) Trade Receivables	5,202.84	3,785.85
(d) Cash And Cash Equivalents	17.91	8.81
(e) Short Term Loans And Advances	1,227.23	355.34
(f) Other Current Assets	-	-
TOTAL	**14,626.00**	**10,338.07**
Significant Accounting Policies		
Notes on Financial Statements		

As per our report of even date attached
For Avnish Sharma & Associates
Chartered Accountants
FRN: 009398N
Peer Review Certificate No. 016702

Avnish Sharma & Associates Chartered Accountants

Rajan Talwar (M.No. 091352)
Partner
UDIN: 26091352NYXMCS2741
Place : Panchkula
Dated : 24.07.2026

For & on behalf of the Board
ASTONEA LABS LIMITED

Astonea Labs Limited

Director

PARDEEP DALAL
DIRECTOR
DIN: 02424111

ASTONEA LABS LIMITED

(Formerly known as Astonea Labs Private Limited)

Registered Office: SCO 321-322, Basement, Sector-35B, Chandigarh, 160022, India

CIN : L24304CH2017PLC041482

STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE HALF YEAR AND YEAR ENDED 31ST MARCH 2026

Rs. in Lakhs

Particulars	Amount in ₹ (lakhs) unless otherwise stated			
	Half Year Ended		Year ended	
	31.03.2026	30.09.2025	31.03.2026	31.03.2025
	(Audited)	(Unaudited)	(Audited)	(Audited)
Income				
Revenue from Operations	8,129.30	6,629.14	14,758.44	9,751.83
Other Income	42.14	9.85	51.99	18.93
Total Income	**8,171.44**	**6,638.99**	**14,810.43**	**9,770.77**
Expenses				
Cost of Material Consumed	5,147.83	5,130.79	10,278.62	5,705.89
Purchase of Traded Goods	-	-	-	982.88
(Increase)/Decrease in inventories of finished goods and traded goods	-166.58	-273.91	-440.49	-21.90
Employee Benefits Expense	409.86	352.90	762.76	670.47
Finance Costs	172.40	153.88	326.28	365.61
Depreciation and Amortization Expense	283.54	215.49	499.03	458.13
Other Expenses	1,939.59	882.49	2,822.08	902.59
Total Expenses	**7,786.64**	**6,461.64**	**14,248.28**	**9,063.66**
Profit/(Loss) before exceptional items and tax	**384.80**	**177.35**	**562.15**	**707.11**
Exceptional Items				-
Add: - Share of profit in Associate	**0.03**		**0.03**	
Profit/(Loss) before tax	**384.83**	**177.35**	**562.18**	**707.11**
Income tax expense				
(1) Current tax	120.93	48.31	169.25	198.84
(2) Deferred tax	-45.90	-12.71	-58.61	-26.78
Profit/(Loss) for the year	**309.79**	**141.75**	**451.54**	**535.05**
Total Profit/(Loss) for the year, net of tax	**309.79**	**141.75**	**451.54**	**535.05**
Earnings per equity share (Nominal Value of Share INR 10 per share)				
Basic earning per share (in absolute figures)	3.08	1.41	4.49	6.94
Diluted earning per share (in absolute figures)	3.08	1.41	4.49	6.94

For Ayush Sharma & Associates
Chartered Accountants
FRN: 0 [illegible]
Peer Review Certificate No. 016702

Rajan Talwar (M.No. 091352)
Partner
UDIN: 26091352NYXMCS2741
Place : Panchkula
Dated : 24.07.2026

For & on behalf of the Board
ASTONEA LABS LIMITED

Astonea Labs Limited

PARDEEP DALAL
DIRECTOR
DIN: 02424111

Director

ASTONEA LABS LIMITED

(Formerly known as Astonea Labs Private Limited)

Registered Office: SCO 321-322, Basement, Sector-35B, Chandigarh, 160022, India

CIN : L24304CH2017PLC041482

CONSOLIDATED STATEMENT OF AUDITED CASH FLOW FOR THE YEAR ENDED 31ST MARCH 2026

Particulars	Amount in ₹(lakhs)	
	For the year ended March 31, 2026	For the year ended March 31, 2025
A. Cash flow from operating activities:		
Profit/(Loss) before tax	562.18	707.09
Adjustments to reconcile profit before tax to net cash flows:	-	-
ADD:		
Depreciation and Amortisation Expense	499.03	458.13
Provision for Gratuity	10.46	2.70
(Profit)/loss on disposal of assets/written off	-	0.08
Finance costs	319.03	328.82
LESS:		
Interest income and Miscellaneous	17.82	16.35
Subsidy Income	4.00	-
Operating profit before working capital adjustments	**1,368.88**	**1,480.47**
Working Capital adjustments:		
Current assets		
(Increase)/Decrease in Trade and other receivables	-1,416.98	-1,242.40
(Increase)/Decrease in Inventories	-425.90	-450.59
(Increase)/Decrease in Advances	-871.89	72.07
Current Liabilities		
Increase/(Decrease) in Trade and other payables	1,423.11	323.70
Increase/(Decrease) in Expenses & other payables	149.38	170.52
Increase/(Decrease) in Short term borrowings	-1,276.33	917.62
Cash generated from operations	-1,049.73	1,271.37
Tax (paid)/refund	169.24	152.02
Tax Adjustment	5.02	-
Interest on WC Loan	140.81	194.42
Net cash flows from operating activities	**-1,364.81**	**924.94**
B. Cash flow from investing activities:		
Proceeds from Investment in shares	-	-
Proceeds from long term Advances & Deposits	15.02	-11.92
Purchase of Property, Plant and Equipment	-1,398.37	-1,079.16
Proceeds from disposal of PPE	-	2.50
Purchase of Other Non-Current Assets	-624.27	-42.21
Interest Received	17.82	16.35
Net cash used in investing activities	**-1,989.80**	**-1,114.43**
C. Cash flow from financing activities:		
Proceeds from issue of capital	3,409.36	120.50
Government grant received	20.00	-
Proceeds/(Repayment) of Secured Loan	192.56	181.37
Proceeds/(Repayment) of Unsecured loans	-80.00	-5.00
Interest paid	-178.22	-134.40
Net cash used in financing activities	**3,363.70**	**162.47**
Net change in cash and cash equivalents (A+B+C)	**9.10**	**-27.02**
Cash and cash equivalents at the beginning of the year	8.81	35.82
Cash and cash equivalents at the year end	**17.91**	**8.80**

As per our report of even date attached
For Avnish Sharma & Associates
Chartered Accountants
FRN - 009588N
Peer Review Certificate No. 016702

Rajan Talwar (M.No. 091352)
Partner
UDIN: 26091352NYXMCS2741
Place : Panchkula
Dated : 24.07.2026

For & on behalf of the Board
ASTONEA LABS LIMITED

Astonea Labs Limited

PARDEEP DALAL
DIRECTOR
DIN: 02424111

Director

ASTONEA LABS LIMITED

(Formerly known as Astonea Labs Private Limited)

Registered Office: SCO 321-322, Basement, Sector-35B, Chandigarh, 160022, India

CIN : L24304CH2017PLC041482

Notes to Consolidated Audited Financial Results for the half year and year ended March 31,2026: -

1 The above consolidated Audited Financial Results of Astonea Labs Limited ("the Company") for the half year ended and Financial year ended 31st March, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 24.07.2026.

2 The consolidated Audited financial results for the Half Year and financial year ended 31st March, 2026, have been prepared in accordance with recognition and measurement principles laid down in the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. The financial results have been prepared in compliance with the applicable Accounting Standards prescribed by the Institute of Chartered Accountants of India.

3 The Statutory Auditors of the Company have carried out the audit of the above consolidated Audited Financial Results for the Half Year and Financial year ended March 31, 2026 in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, on which they have issued an unmodifed opinion.

4 The following matter of emphasis are reported in the Audit Report:-
a) A major fire incident occurred on 27th April 2026 in the factory premises of the company , which effected the functioning of the plant. The fire caused substantial damage to factory Building , Plant and Machinery , Stocks & other records lying at the factory premises and the management has intimated loss of Rs 9.39 crores and the claim is yet to be filed with insurance company . The Fire loss has not impacted basis of functioning and the status of the company as going concern.
b) During the year, the company had entered into a sales agreement vide Distribution, Marketing & Brand License Agreement ("Agreement") for certain products with Astonea One Private Limited, an associate concern to sell their products as non-exclusive distributor on commission basis to be paid directly/indirectly to Astonea One Pvt. Ltd. The total sales after this agreement dated 01.08.2025 were for Rs.41.40 crores on which direct/indirect commission of Rs. 15.43 crores were paid. These transaction are to be reported at arm length prices by management.

5 Astonea Labs Limited successfully debuted on the BSE SME platform on June 3rd, 2025 and Pursuant to the MCA notification dated 16th February, 2015, companies which shares are listed on the SME Exchange, as referred to in Chapter IX of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 are exempted from the mandatory adoption of Indian Accounting Standards (Ind AS). However, the Company has voluntarily adopted for IND AS effective from F.Y 2026-27.

6 During the Financial Year 2025-26, Astonea Labs Limited ("the Company") has incorporated a wholly-owned foreign subsidiary, Astonea LLC in the Sheridan, Wyoming , United States of America (USA) , pursuant to the Certificate of Incorporation dated 25th January, 2026. The Company has borne expenses of Rs.60,798 (USD 660.89) for incorporation but has not subscribed any capital. All the preliminary expenses spent for the creation of this company has been borne by the directors. Since no capital is Subscribed /Invested and no business has been started in Astonea LLC as of now, hence no consolidation of accounts has been done in this year.

7 The Company is currently engaged in the manufacture and sale of cosmetics & Pharmaceutical Products. As per guidelines contain in AS-17 (Segment reporting), the company is operating in a single segment mainly in manufacture and sale of drugs & cosmetics. There is no separate reportable segment except geographically secondary segment of export sales and hence not reported seperately. Also, due to the unavailability of separate information for manufacturing and trading-related expenses, these activities are accounted for as one segment.

8 The Company does not have exceptional or extraordinary items to report for the above period.

9 In the previous financial year, traded purchases were not bifurcated separately. However, for the purpose of better comparability and enhanced disclosure, the traded purchases for the current financial year have been bifurcated. Accordingly, the figures for the previous financial year have also been reclassified to reflect a similar bifurcation and ensure a consistent comparative presentation.

10 In terms of Regulation 33(2)(a) of the Securities and Exchange Board of India (Listing Obligations and disclosure requirements) Regulations, 2015, The Director and the Chief Financial Officer of the company have certified that the above financial results do not contain any false or misleading statements or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

11 The Weighted average number of equity shares outstanding during the year has been considered for calculating the basic and diluted earnings per share in accordance with the Accounting Standard (AS) 20.

12 As per AS 26 : Intangible Assets entity has internally generated a brand for which research was conducted from 01.01.2021 till 31.03.2024. Expense incurred during the research phase has been charged to profit and loss account. Development phase started from 01.04.2024 and will continue till 31.03.2027. Expense incurred during the development phase are and will be be capitalised in the intangible asset. During the year, entity has incurred Rs. 3.27 crores which has been capitalised as CWIP which includes borrowing cost of Rs.7.90 lakh.

13 The Annual General Meeting of the company for Financial Year ended 31.03.2025 was postponed for which approval of Registrar of Companies, Chandigarh was received vide order dt 11.09.2025. The Annual General Meeting had been held on 27.12.2025.

14 The Share issue and Administrative Expenses amounting to Rs 3,86,61,128/- incurred for Initial Public Offer includes a sum of Rs 29,50,000/- spent towards- Listing fee on Stock Exchanges, approval from stock exchange and SME One time Listing Fee. Out of which Rs. 3,57,14,128 has been deducted from Share Premium Account and the balance of Rs 29,50,000 has been accounted for in Profit & Loss Account as per applicable regulations.

15 The Company was listed on the Stock Exchange on 03.06.2025. In connection with the Public Issue, equity shares having a face value of Rs 10 each were issued at a share premium of Rs 125 per equity share, resulting in an issue price of Rs 135 per share. The public issue comprised of 27,90,000 equity shares issued through a Fresh Issue. The proceeds from the Fresh Issue were received by the Company (Rs 37,66,50,000/-) . The public issue was undertaken in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Consequently, these financial statements represent the first set of results as a listed entity.

SHARMA & ASSOCIATES CHARTERED ACCOUNTANTS

16 The utilization of IPO proceeds is summarised as under:-

Object	Original Allocation (Rs.)	*Revised Allocation	Total Utilised Amount till 31.03.2026 (Rs.)	Total Unutilised Amount till 31.03.2026 (Rs.)
Funding of expenses proposed to be incurred towards registration in Bolivia, South America	1,28,97,000	75,00,000.00	8,34,230.00	66,65,770.00
Purchase and installation of plant and machineries for ointment production for the purpose of export in accordance with the international standards and protocols, on the 2nd floor of the Existing Premises.	5,23,40,000	3,00,57,814.00	3,00,57,814.00	-
Advertising, marketing and brand building	4,95,15,000	2,00,15,000.00	2,00,15,000.00	-
Investment in procuring hardware and software	68,38,000	15,44,825.00	15,44,825.00	-
Funding of working capital requirements	19,75,00,000	19,75,00,000.00	19,75,00,000.00	-
General corporate purposes	1,98,81,000	1,98,53,361.00	89,85,129.00	1,08,68,232.00
Issue Expenses	3,76,79,000	3,76,79,000.00	3,76,79,000.00	-
*Investment in Equity Stake of Damaira Pharmaceuticals Private Limited	-	6,25,00,000.00	6,25,00,000.00	-
Total	37,66,50,000	37,66,50,000.00	35,91,15,998.00	1,75,34,002.00

* The Board of Directors of the Company, after due consideration and deliberation, in board meeting dated 27.02.2026 has approved a variation in the utilis.ation of the proceeds raised through the Initial Public Offering (IPO), with respect to the objects as disclosed and approved in the Prospectus.

**The said proposed variation in the utilisation of IPO proceeds was placed befor ethe shareholders for their approval at the Extra-Ordinary General Meeting (EGM) of the Company held on 27.03.2026, in accordance with applicable statutory and regulatory requirements. Pursuant to the requisite approvals obtained from both the Board of Directors and the Shareholders of the Company, the revised object of utilisation has been duly implemented.

***Accordingly, the entire amount pertaining to the approved deviation has been fully utilised towards the acquisition of an equity stake in Damaira Pharmaceuticals Private Limited, as Associate Company on 31.03.2026, in line with the approved revised object of utilisation of IPO proceeds as per the details below.

****The Unutilised IPO proceeds amounting to Rs 1,75,34,002/- have been kept in Regular Current Account Account No 50200088242121 (DOD) as per SEBI ICDR regulations.

The Company has made an investment in Securities of "Damaira Pharmaceuticals Private Limited as follows:

Date of Investment	Nature of Investment	No. of Shares	Amount (In Lakhs)
31.03.2026	Equity(25.74%)	52,00,000	625.00

17 These Audited consolidated financial results for the Half year ended and year ended 31st March,2026 have been rounded off to nearest rupees in lakhs upto two decimal places, which is in line with the requirement of AS Schedule III of the Companies Act, 2013. Accordingly, figures of the corresponding periods presented have also been aligned to the latest period presented.

18 Figures pertaining to previous year/periods have been regrouped/rearranged, reclassified and restated wherever necessary to make them comparable with those of current year/period.

19 The Audited consolidated Financial Results for the Half year and Financial year ended March 31, 2026 are available on the website of BSE Limited at http://www.bseindia.com and on the website of the Company at https://www.astonea.org.

20 The previous year figure for the year ended 31.03.2025 were only for Astonea Labs Limited as the investment in associate (Damaira Pharmaceutical Pvt. Ltd.) was made on 31.03.2026. For the year ended March, 2026 the Company has prepared and presented consolidated financial results, incorporating the financial information of its associate entity, as applicable.

During the preparation of the consolidated financial results, the Company has included its share of the Associate Company's profit for one day, representing the period from the date on which significant influence was obtained up to the reporting date i.e 31.03.2026.

For Avnish Sharma & Associates
Chartered Accountants
FRN 009398N
Peer Review Certificate No. 016702

Rajan Talwar (M.No. 091352)
Partner
UDIN: 26091352NYXMCS2741
Place : Panchkula
Dated : 24.07.2026

For & on behalf of the Board
ASTONEA LABS LIMITED

Astonea Labs Limited

PARDEEP DALAL
DIRECTOR
DIN: 02424111

astonea
Astonea Labs Limited

Date: 24th July, 2026
To,
BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001

Scrip Code: 544409
ISIN: INE0TG901011

Subject:Declaration in terms of Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

In terms of the second proviso to Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we declare that **M/s. AVNISH SHARMA & ASSOCIATES, Chartered Accountants, Haryana**, the Statutory Auditors of the Company, have submitted their Audit Reports on the Audited Consolidated Financial Results of the Company for the Financial Year ended **March 31, 2026** with **unmodified opinion(s)**.

This declaration is issued in compliance with the provisions of Regulation 33(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

Request you to kindly take the same on record.

Thanking you,
For Astonea Labs Limited
Astonea Labs Limited

P. Dalal Director
PARDEEP DALAL
Director
DIN: 02424111

ANNEXURE – II
DETAILS OF DIRECTOR PROPOSED FOR RE-APPOINTMENT AS PER SEBI LODR REQUIREMENTS

Details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated 13th July, 2023

Sr. No.	Particulars	Details
1.	Name of Director	Ms. Pooja Singh
2.	DIN	10547745
3.	Reason for Change	Re-appointment due to retirement by rotation, subject to approval of members at the ensuing Annual General Meeting.
4.	Date of Re-appointment	Effective from the date of approval by the members at the ensuing Annual General Meeting.
5.	Term of Re-appointment	As per the provisions of the Companies Act, 2013 and Articles of Association of the Company.
6.	Brief Profile	Ms. Pooja Singh is associated with the Company as a Director and possesses experience in business operations, management and strategic decision-making.
7.	Disclosure of Relationship with Directors	Ms. Pooja Singh is not related to any other Director of the Company.
8.	Debarment Status	Ms. Pooja Singh is not debarred from holding the office of Director by SEBI or any other statutory authority.

ANNEXURE – III
BRIEF DETAILS OF ALTERATION OF OBJECT CLAUSE OF MEMORANDUM OF ASSOCIATION OF THE COMPANY

Details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated 13th July, 2023

Sr. No.	Particulars	Details
1.	Reason for Change	Alteration of Object Clause of the Memorandum of Association ("MOA") to align with the proposed expansion and diversification of the Company's business activities in pharmaceutical, healthcare, nutraceutical, ayurvedic, herbal and allied sectors.
2.	Details of Amendment in Object Clause	Existing Clause III(A) of the MOA is proposed to be substituted to include activities relating to manufacturing, formulation, processing, development, refining, import, export, wholesale and retail trading of pharmaceuticals, medicines, healthcare products, nutraceuticals, ayurvedic, herbal and dietary supplement products and other allied products.
3.	Objects and Effects of Alteration	The proposed alteration will enable the Company to undertake manufacturing, marketing, distribution, promotion and sale of pharmaceutical, healthcare and allied products through various lawful distribution channels.
4.	Date of Approval by Board of Directors	24th July, 2026
5.	Date of Approval by Shareholders	Approval to be obtained through Special Resolution at the ensuing General Meeting.
6.	Nature of Approval Required	Approval of members by way of Special Resolution pursuant to Section 13 of the Companies Act, 2013.

ANNEXURE – IV
INTIMATION OF SCHEDULE OF 9TH ANNUAL GENERAL MEETING OF THE COMPANY

Pursuant to the provisions of the Companies Act, 2013 and applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the 9th Annual General Meeting ("AGM") of Astonea Labs Limited ("the Company") is scheduled to be held as per the details mentioned below:

Sr. No.	Particulars	Details
1.	Name of the Company	Astonea Labs Limited
2.	Type of Meeting	9th Annual General Meeting ("AGM")
3.	Day and Date of AGM	Friday, 21st August, 2026
4.	Time of AGM	11:30 A.M.
5.	Venue of AGM	Mercure Hotel, Plot No. 51, Near Tribune Chowk, Industrial Area Phase II, Chandigarh – 160002
6.	Mode of AGM	Physical Mode
7.	Cut-off Date for determining eligibility for Remote E-voting	Friday, 14th August, 2026
8.	Remote E-voting Facility	The Company shall provide the facility of remote e-voting to its members in respect of the businesses to be transacted at the 9th Annual General Meeting in accordance with the applicable provisions of the Companies Act, 2013 and rules made thereunder.
9.	E-Voting Begins	Tuesday, 18th August, 2026 at 09:00 A.M.
10.	E-Voting Ends	Thursday, 20th August, 2026 at 05:00 P.M.
11.	E-voting Agency	National Securities Depository Limited (NSDL)
12.	Scrutinizer for E-voting Process	Mr. Sahil Malhotra (Membership No. A38204 / COP No. 14791)
13.	Notice of AGM	Pursuant to the provisions of Section 91 of the Companies Act, 2013 and Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Register of Members and Share Transfer Books of the Company shall remain closed from Saturday, August 15, 2026 to Friday, August 21, 2026 (both days inclusive) for the purpose of the 9th Annual General Meeting
14.	Notice of AGM	The Notice of the 9th Annual General Meeting along with the explanatory statement pursuant to Section 102 of the Companies Act, 2013 and other relevant documents shall be sent to the members of the Company in accordance with the applicable provisions of the Companies Act, 2013, rules made thereunder and Secretarial Standard-2 ("SS-2") on General Meetings issued by the Institute of Company Secretaries of India.
15.	Declaration of Voting Results	The voting results along with the Scrutinizer's Report shall be submitted to the Stock Exchange within the prescribed timelines in accordance with the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Annexure-V

Details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026

Sr. No.	Particulars	Details
1.	Name	Mr. Rajan Talwar, Partner, M/s. Avnish Sharma & Associates, Chartered Accountants (Firm Registration No. 009398N)
2.	Reason for change viz. ~~Appointment~~, Reappointment, ~~resignation, removal, death or otherwise~~	Re-appointment of M/s. Avnish Sharma & Associates, Chartered Accountants as the Tax Auditor of the Company for the Tax Year 2026-27 (corresponding to the Financial Year ending 31st March, 2027) for conducting tax audit under the applicable provisions of the Income-tax Act, 2025, including Section 63 thereof, and undertaking such other certifications, reports and compliances as may be required under applicable law.
3.	Date of ~~Appointment~~ / Re-appointment / ~~cessation & Terms of appointment / Re-appointment~~	The re-appointment of M/s. Avnish Sharma & Associates, Chartered Accountants as the Tax Auditor of the Company was approved by the Board of Directors on 24th July, 2026, pursuant to the amendment approved to Item No. 15 of the Board Resolution dated 30th May, 2026. The appointment shall be for the Tax Year 2026-27 (corresponding to the Financial Year ending 31st March, 2027), on such terms and conditions as mutually agreed between the Company and the Tax Auditor.
4.	Term of re-appointment	Appointment as Tax Auditor of the Company for the Tax Year 2026-27 (corresponding to the Financial Year ending 31st March, 2027).
5.	Brief profile	M/s. Avnish Sharma & Associates is a Chartered Accountants firm having experience in the areas of taxation, audit, compliance management, financial advisory and regulatory consultancy services. The firm provides professional services relating to tax audits, certifications, regulatory compliances and advisory support to various organizations.
6.	Disclosure of relationships between Directors	Not Applicable
7.	Relation with the Company	M/s. Avnish Sharma & Associates, Chartered Accountants is not related to any Director or Key Managerial Personnel of the Company and is associated with the Company in the capacity of Tax Auditor.